Lv33
386 积分 2023-05-06 加入
Cancer burden and control in China: landscape, trends and challenges
1天前
已完结
TACE联合仑伐替尼、免疫治疗对经免疫联合贝伐珠单抗治疗失败后的不可切除肝细胞癌患者的治疗效果与安全性分析
4天前
已完结
Efficacy of regorafenib following first-line immune checkpoint inhibitor failure in patients with advanced hepatocellular carcinoma: A multicenter study
4天前
已完结
[Chinese multidisciplinary expert consensus on combined immunotherapy for hepatocellular carcinoma(2023 version)]
7天前
已完结
Systemic treatment patterns and clinical outcomes in hepatocellular carcinoma: A multicenter real-world study from China (STAR-HCC)
7天前
已完结
Systemic therapy sequence and outcomes in unresectable hepatocellular carcinoma: results from the multicenter Tokai Post ICI Sequential Therapy Registry cohort
7天前
已完结
Systemic treatment patterns and clinical outcomes in hepatocellular carcinoma: A multicenter real-world study from China (STAR-HCC)
10天前
已完结
Innate and Adaptive Immune Dysregulation in Women with Recurrent Implantation Failure
13天前
已完结
Innate and Adaptive Immune Dysregulation in Women with Recurrent Implantation Failure
13天前
已完结
Prednisone vs Placebo and Live Birth in Patients With Recurrent Implantation Failure Undergoing In Vitro Fertilization
13天前
已完结
皖公网安备34019202002308
